For sponsors and CROs · San Jose, CA

Enrollment you can plan around.

A physician-led research site with its own psychiatry practice feeding the registry, a 22-person team of physician-trained coordinators, and a track record of finishing above target. 8,500 sq ft directly across from Good Samaritan Hospital.

Start a feasibility conversation Site profile (PDF)

98.8%Retention across recent programs

400%Of expected enrollment, six recent programs

46Trials as PI since 2020

22On-site team, physician-trained CRCs

2 wksTypical start-up

Start here

Four things sponsors ask first

Pick a block for the short answer, or follow its link for the full detail further down.

Why choose Lumos

See the track record

EffectiveEfficient enrollment and study execution.

Consistently deliveredEvery recent sponsor program finished above its contracted target.

Physician-led qualityEvery coordinator, the Site Director and the Study Director is an internationally trained physician.

Well-controlled placebo responseRigorous rater training and patient selection, which shows in the quality of the data a study ends with.

FDA auditedHighest-enrolling site for an approved drug.

98.8% retentionAcross recent programs.

Experienced investigator46 industry-sponsored trials as principal investigator since 2020.

Infrastructure

See the facility

8,500 sq ft facilityBuilt for early and late phase studies.

2 dosing roomsPurpose-built for long visit days.

2 inpatient roomsPrivate and monitored, expandable to 5.

On-site labsDraws, processing and safety monitoring.

English and Spanish staffBilingual team on site.

Central IRBNo local IRB delay.

2-week start-upFrom contract to ready.

Across from Good Samaritan Hospital24/7 emergency department.

PET, DEXA and MRIImaging center two minutes away.

Patients

See the population

Deep pool of research-naive patientsParticipants new to clinical trials, which reduces professional-subject risk and supports cleaner data.

Diverse patient populationRepresentative enrollment that supports sponsor diversity goals, with bilingual English and Spanish staff.

Experience

See trials by indication

Psychiatry

Metabolic

Schizophrenia

Trials as PI3

Enrolled5

Against target2

Of target250%

One sponsor program.

MDD

Trials as PI18

Enrolled23

Against target15

Of target153%

Two sponsor programs contributed the enrollment figure.

TRD

Trials as PI3

Run inside our major depressive disorder programs, so these trials also sit within the MDD count.

PTSD

Trials as PI3

Also counted within the other CNS group in the chart below.

OCD

Trials as PI3

Panic disorder

Trials as PI2

Anxiety

Trials as PI7

Enrolled153

Against target35

Of target437%

Covers anxiety disorders including social anxiety. The enrollment figure is from two social anxiety programs.

Obesity

Trials as PI1

Enrolled107

Against target20

Of target535%

One sponsor program.

Industry-sponsored trials with Dr. Maitra as principal investigator since 2020, Phase II and Phase III. Full protocol list, per-study phases and enrollment detail on request under CDA.

Request a feasibility call

Why sponsors choose Lumos

Three things a feasibility form can’t show you

The registry is our own practice

Lumos Psychiatric Services shares the building, the team and the record. Eligible patients are found in routine care and pre-screened by a physician, not recruited by advertising.

Every coordinator is a physician

All eight CRCs, the Site Director and the Study Director are internationally trained MDs. Protocol judgement, adverse-event recognition and source quality come with the job.

Comorbidity handled in-house

Psychiatric and metabolic assessments run on site, so eligibility decisions hold and retention stays high on CNS and cardiometabolic protocols alike.

Track record

Every recent program enrolled above target

Six sponsor programs, 72 participants expected under contract, 288 enrolled. Over-enrollment is the pattern, not a one-off. Sponsor names on request.

535%of target enrollment

Obesity1 sponsor program

Expected20

Enrolled107

437%of target enrollment

Social anxiety disorder2 sponsor programs

Expected35

Enrolled153

153%of target enrollment

Major depressive disorder2 sponsor programs

Expected15

Enrolled23

250%of target enrollment

Schizophrenia1 sponsor program

Expected2

Enrolled5

Expected is the enrollment written into each contract; where two sponsors ran the same indication their programs are combined. Enrolled is what the site delivered.

Trials as PI by indication

Industry-sponsored, 2020 to date; protocol list on request.

Major depressive disorder18

Anxiety disorders, incl. social anxiety7

Pediatric psychiatry6

Other CNS and diagnostic5

OCD3

Schizophrenia3

Panic disorder2

Motion sickness2

The population behind our enrollment

Screening starts from identified patients in our own practice, not cold advertising.

Deep pool of research-naive patients

Participants new to clinical trials, which reduces professional-subject risk and supports cleaner data.

Diverse patient population

Representative enrollment that supports sponsor diversity goals, with bilingual English and Spanish staff on site.

At a glance

Site profile

Laid out the way your feasibility form is, so you can pre-qualify us before you send one.

Site: Lumos Clinical Research Center (East Ivy Panacea Inc), founded 2020
Address: 2516 Samaritan Drive, Suite B, San Jose, CA 95124, directly across from Good Samaritan Hospital
Research line: (408) 668-2712 · research@lumosclinical.com
Principal investigator: Sarbani Maitra, MD. Medical Director, board certified by the American Board of Psychiatry and Neurology
Sub-investigator: Joseph M. Isaacson, MD, FACP, FACR. Board certified in Obesity Medicine; Adjunct Associate Clinical Professor, Stanford University School of Medicine; sub-I since 2021
Site leadership: Darya Babina, MD, PhD (Site Director) · Shazia Fayyaz, MD (Study Director)
Studies: 46 industry-sponsored trials as principal investigator since 2020: 20 active, 26 completed
Phases: Phase II and Phase III programs; diagnostic reference-range and digital therapeutic studies
Therapeutic areas: Psychiatry and CNS (MDD, GAD, ADHD, bipolar, OCD, PTSD, schizophrenia, panic, social anxiety, autism), obesity and cardiometabolic (obesity, type 1 and 2 diabetes, GLP-1), neurology (migraine, Alzheimer’s)
Research staff: 22 on site: 8 clinical research coordinators (all internationally trained physicians), 8 research assistants, site and study directors
Retention: 98.8% across recent programs
Languages: English and Spanish, on site
IRB: Central IRB
Start-up: About 2 weeks: single-site decisions, in-house regulatory and budget review, no build-out needed
CTMS / eSource: Aega, our in-house CTMS and eSource
PI credentials: ABPN board certified · California and Tennessee licenses · DEA Schedule I researcher and Schedule II–V registrations · GCP certification current through August 2029 · IATA shipping certification
Regulatory history: FDA inspection history and Form 1572s available on request under CDA

Principal investigator

Sarbani Maitra, MD

Medical Director and co-founder of Lumos Clinical Research Center, principal investigator on 46 industry-sponsored trials since 2020 across depression, anxiety, OCD, schizophrenia, panic and pediatric psychiatry. Board certified by the American Board of Psychiatry and Neurology; psychiatry residency and chief-resident roles at Meharry Medical College; M.D., American University of the Caribbean.

Before psychiatry, a senior clinical researcher and study coordinator on NIH- and industry-funded trials at Meharry’s Center for Women’s Health Research, with peer-reviewed publications. She has run a site from both sides of the table.

ABPN board certifiedDEA Schedule I researcherGCP through 2029CA & TN licensed

Request the CV

Facility

One site, purpose-built for long visit days

Approximately 8,500 sq ft on one floor: assessment, dosing, inpatient observation, lab and monitoring under one roof, free parking at the door, and a 24/7 emergency department across the street.

2Dosing rooms

2 → 5Inpatient rooms, expandable

−80°CFreezers: −20, −70, −80

2 minTo MRI, PET-CT and DEXA

Dosing rooms2

Inpatient rooms, private and monitored2 today, expandable to 5

On-site clinical laboratoryDraws, sample processing, safety monitoring

Sample handlingAmbient centrifuge; −20°C, −70°C and −80°C freezers

Investigational productLocked IP cabinet, Schedule I–V

EKGOn site

Monitor workspacePrivate monitoring and source-document room

Also on siteInterventional treatment room, TMS suite

ImagingX-ray, CT, MRI, PET-CT and DEXA at the imaging center across the corridor, two minutes away

Emergency backup24/7 emergency department directly across the street

ParkingFree, at the door

Walk the site

See the rooms your study would run in

A 3D walk-through of the real suite: reception, screening, dosing and monitoring spaces, exactly as your monitor will find them.

Inside the site

The rooms.

Operations and quality

How we run

Start-up in about two weeks

Single-site decision making, in-house regulatory and budget review, central IRB. No build-out required to begin.

Physician-trained coordinators

Every coordinator, the Site Director and the Study Director are internationally trained physicians. GCP certification current.

In-house screening

Metabolic and psychiatric assessments run on site, removing ineligible candidates early and protecting eligibility decisions.

Recruitment from our own base

Enrollment comes largely from the site’s own patient registry and community, not paid advertising.

Retention by design

Visit scheduling built around long study days and repeat visits; free parking at the door; the same coordinator each time.

eSource on Aega

Our own CTMS and eSource platform; monitors get a private workspace and clean source on every visit.